162375-26-0

Basic information

• Product Name: 2'-O-(tert-butyldimethylsilyl)-10-deacetylpaclitaxel
• Synonyms: 2'-O-(tert-butyldimethylsilyl)-10-deacetylpaclitaxel
• CAS NO: 162375-26-0
• Molecular Weight: 926.146
• Mol File: 162375-26-0.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2'-O-(tert-butyldimethylsilyl)-10-deacetylpaclitaxel(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-O-(tert-butyldimethylsilyl)-10-deacetylpaclitaxel(162375-26-0)
• EPA Substance Registry System: 2'-O-(tert-butyldimethylsilyl)-10-deacetylpaclitaxel(162375-26-0)

Safety Data

• Hazardous Substances Data: 162375-26-0(Hazardous Substances Data)

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 33069-62-4 taxol 
• 114655-02-6 2'-O-(tert-butyldimethylsilyl)paclitaxel 
• 78432-77-6 10-deacetylpaclitaxel 

Downstream Products

• 162809-97-4 2'-O-(tert-butyldimethylsilyl)-10-deacetyl-7-O-triethylsilylpaclitaxel 
• 1151989-43-3 C₇₅H₁₀₂N₂O₂₂S₂Si 
• 1051405-78-7 C₃₉H₄₆O₁₂ 
• 1051405-72-1 C₄₇H₅₃NO₁₄ 
• 1051405-75-4 C₅₅H₅₉NO₁₅ 
• 1052091-65-2 C₆₂H₇₁NO₁₇ 
• 849213-05-4 2-O-TES-7-O-methylthiomethyl-9-α-OH-10-epi-paclitaxel 
• 849213-04-3 2'-O-TES-9-α-OH-10-epi-paclitaxel 
• 849213-07-6 C₅₄H₆₇NO₁₄Si 
• 849213-06-5 7-O-methylthiomethyl-9-α-OH-10-epi-paclitaxel 

Relevant articles and documents

Synthesis and cytotoxicity of 7,9-O-linked macrocyclic C-Seco taxoids

A series of novel 7,9-O-linked macrocyclic taxoids together with modification at the C2 position were synthesized, and their cytotoxicities against drug-sensitive and P-glycoprotein and βIII-tubulin overexpressed drug-resistant cancer cell lines were eval

TAXANE ANALOGS FOR THE TREATMENT OF BRAIN CANCER

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a s

BIOLOGICALLY ACTIVE TAXANE ANALOGS AND METHODS OF TREATMENT BY ORAL ADMINISTRATION

The present invention relates to a novel chemical compound of formula S-(I) for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.